46 research outputs found
PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer
Background: The sodium/iodide symporter (NIS) is a membrane glycoprotein mediating active
iodide uptake in the thyroid gland and is the molecular basis for radioiodide imaging and therapeutic
ablation of thyroid carcinomas. NIS is expressed in the lactating mammary gland and in many human
breast tumors, raising interest in similar use for diagnosis and treatment. However, few human
breast tumors have clinically evident iodide uptake ability. We previously identified PI3K signaling
as important in NIS upregulation in transgenic mouse models of breast cancer, and the PI3K
pathway is commonly activated in human breast cancer.
Methods: NIS expression, subcellular localization, and function were analyzed in MCF-7 human
breast cancer cells and MCF-7 cells stably or transiently expressing PI3K p110alpha subunit using
Western blot of whole cell lysate, cell surface biotinylation Western blot and immunofluorescence,
and radioiodide uptake assay, respectively. NIS localization was determined in a human breast
cancer tissue microarray using immunohistochemical staining (IHC) and was correlated with preexisting
pAkt IHC data. Statistical analysis consisted of Student's t-test (in vitro studies) or Fisher's
Exact Test (in vivo correlational studies).
Results: In this study, we demonstrate that PI3K activation in MCF-7 human mammary carcinoma
cells leads to expression of underglycosylated NIS lacking cell surface trafficking necessary for
iodide uptake ability. PI3K activation also appears to interfere with cell surface trafficking of
exogenous NIS as well as all-trans retinoic acid-induced endogenous NIS. A correlation between
NIS expression and upregulation of PI3K signaling was found in a human breast cancer tissue
microarray.
Conclusion: Thus, the PI3K pathway likely plays a major role in the discordance between NIS
expression and iodide uptake in breast cancer patients. Further study is warranted to realize the
application of NIS-mediated radioiodide ablation in breast cancer
Combined Vorinostat and Chloroquine Inhibit Sodium Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo
Purpose Patients with aggressive thyroid cancer are frequently failed by the central therapy of ablative radioiodide (RAI) uptake, due to reduced plasma membrane (PM) localization of the sodium/iodide symporter (NIS). We aimed to understand how NIS is endocytosed away from the PM of human thyroid cancer cells, and whether this was druggable in vivo.Experimental DesignInformed by analysis of endocytic gene expression in patients with aggressive thyroid cancer, we used mutagenesis, NanoBiT interaction assays, cell surface biotinylation assays, RAI uptake and NanoBRET to understand the mechanisms of NIS endocytosis in transformed cell lines and patient-derived human primary thyroid cells. Systemic drug responses were monitored via 99mTc pertechnetate gamma counting and gene expression in BALB/c mice.ResultsWe identify an acidic dipeptide within the NIS C-terminus which mediates binding to the 2 subunit of the Adaptor Protein 2 (AP2) heterotetramer. We discovered that the FDA-approved drug chloroquine modulates NIS accumulation at the PM in a functional manner that is AP2 dependent. In vivo, chloroquine treatment of BALB/c mice significantly enhanced thyroidal uptake of 99mTc pertechnetate in combination with the histone deacetylase (HDAC) inhibitor vorinostat/ SAHA, accompanied by increased thyroidal NIS mRNA. Bioinformatic analyses validated the clinical relevance of AP2 genes with disease-free survival in RAI-treated DTC, enabling construction of an AP2 gene-related risk score classifier for predicting recurrence.ConclusionsNIS internalisation is specifically druggable in vivo. Our data therefore provide new translatable potential for improving RAI therapy using FDA-approved drugs in patients with aggressive thyroid cancer.<br/
Microarray analysis of genes associated with cell surface NIS protein levels in breast cancer
<p>Abstract</p> <p>Background</p> <p>Na<sup>+</sup>/I<sup>- </sup>symporter (NIS)-mediated iodide uptake allows radioiodine therapy for thyroid cancer. NIS is also expressed in breast tumors, raising potential for radionuclide therapy of breast cancer. However, NIS expression in most breast cancers is low and may not be sufficient for radionuclide therapy. We aimed to identify biomarkers associated with NIS expression such that mechanisms underlying NIS modulation in human breast tumors may be elucidated.</p> <p>Methods</p> <p>Published oligonucleotide microarray data within the National Center for Biotechnology Information Gene Expression Omnibus database were analyzed to identify gene expression tightly correlated with NIS mRNA level among human breast tumors. NIS immunostaining was performed in a tissue microarray composed of 28 human breast tumors which had corresponding oligonucleotide microarray data available for each tumor such that gene expression associated <it>w</it>ith cell surface NIS protein level could be identified.</p> <p>Results and Discussion</p> <p>NIS mRNA levels do not vary among breast tumors or when compared to normal breast tissues when detected by Affymetrix oligonucleotide microarray platforms. Cell surface NIS protein levels are much more variable than their corresponding NIS mRNA levels. Despite a limited number of breast tumors examined, our analysis identified cysteinyl-tRNA synthetase as a biomarker that is highly associated with cell surface NIS protein levels in the ER-positive breast cancer subtype.</p> <p>Conclusions</p> <p>Further investigation on genes associated with cell surface NIS protein levels within each breast cancer molecular subtype may lead to novel targets for selectively increasing NIS expression/function in a subset of breast cancers patients.</p
Quantitative characterization of cell behaviors through cell cycle progression via automated cell tracking.
Cell behaviors are reflections of intracellular tension dynamics and play important roles in many cellular processes. In this study, temporal variations in cell geometry and cell motion through cell cycle progression were quantitatively characterized via automated cell tracking for MCF-10A non-transformed breast cells, MCF-7 non-invasive breast cancer cells, and MDA-MB-231 highly metastatic breast cancer cells. A new cell segmentation method, which combines the threshold method and our modified edge based active contour method, was applied to optimize cell boundary detection for all cells in the field-of-view. An automated cell-tracking program was implemented to conduct live cell tracking over 40 hours for the three cell lines. The cell boundary and location information was measured and aligned with cell cycle progression with constructed cell lineage trees. Cell behaviors were studied in terms of cell geometry and cell motion. For cell geometry, cell area and cell axis ratio were investigated. For cell motion, instantaneous migration speed, cell motion type, as well as cell motion range were analyzed. We applied a cell-based approach that allows us to examine and compare temporal variations of cell behavior along with cell cycle progression at a single cell level. Cell body geometry along with distribution of peripheral protrusion structures appears to be associated with cell motion features. Migration speed together with motion type and motion ranges are required to distinguish the three cell-lines examined. We found that cells dividing or overlapping vertically are unique features of cell malignancy for both MCF-7 and MDA-MB-231 cells, whereas abrupt changes in cell body geometry and cell motion during mitosis are unique to highly metastatic MDA-MB-231 cells. Taken together, our live cell tracking system serves as an invaluable tool to identify cell behaviors that are unique to malignant and/or highly metastatic breast cancer cells
Expression, Exon-Intron Organization, and Chromosome Mapping of the Human Sodium Iodide Symporter
Cloning of the human taurine transporter and characterization of taurine uptake in thyroid cells11The cDNA sequence of HTAU has been deposited in EMBL.
AbstractA cDNA clone encoding a taurine transporter, designated HTAU, has been isolated from human thyroid. It contains an open reading frame encoding a protein of 619 amino acids with a calculated molecular weight of 69,675 Da. The predicted amino acid sequence of HTAU is highly homologous to those of dog kidney and rat brain. The HTAU mRNA was detectable in various human tissues examined. Transient expression of HTAU in COS-7 cells conferred a higher taurine uptake. The taurine uptake in FRTL-5 cells appears to be regulated by thyrotropin through cAMP. Finally, a higher taurine uptake may be associated with a higher proliferation rate in some cultured cell lines